

ASX ANNOUNCEMENT

CELLMID APPOINTS DR MARTIN CROSS AS NON-EXECUTIVE DIRECTOR

SYDNEY, Monday 16 October 2017, Cellmid Limited (ASX: CDY) is pleased to advise that it has appointed Dr Martin Cross as non-executive director, effective immediately. Dr Cross is a highly regarded pharmaceutical executive with over 30 years' experience including corporate and industry leadership roles in global business development, marketing, sales, product development and management roles.

From 2010 to 2013 Dr Cross was Managing Director of Alphapharm, the largest generics company in Australia, with responsibility for 750 employees and sales of over US \$500m per annum. During the same period he was Chairman of both the Generics Medicine Industry Association and the Pharmaceutical Industry Council. From 2013 to 2015 Dr Cross was the Chairman of Medicines Australia, the country's peak body representing the pharmaceutical industry, including multinational companies.

Earlier in his career Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003 in Switzerland.

Dr Cross has extensive experience in the entire consumer health product supply chain including manufacturing, fulfilment, distribution, marketing and sales. He has a thorough appreciation of trends in consumer markets and how consumer behaviour is influenced through traditional and digital marketing.

Educated at the University of Aberdeen (UK), where he obtained his PhD in microbiology, Dr Cross has subsequently undertaken management training at Harvard Business School. He is currently non-executive director of Oncosil Limited and is on the UTS Pharmacy Advisory Board, in addition to being a Fellow of the Australian Institute of Company Directors.

"I am very pleased to join Cellmid at this exciting stage of its development, with a clear business focus on increasing distribution and sales in consumer health and delivering value from the broad intellectual property portfolio around midkine" said Dr Cross.

"We are delighted to welcome Martin onto the Board as non-executive director" said Chairman of Cellmid Dr David King. "His broad experience in the global pharmaceutical industry and understanding of the consumer health space will be invaluable in both our midkine and Advangen businesses" he added.

End

Contact:

Dr David King, Chairman
T +612 9221 683

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.